Yang Chi-Fu Jeffrey, Aibel Kelli, Meyerhoff Ryan, Wang Frances, Harpole David, Abernethy Amy P, LeBlanc Thomas W
Duke Cancer Institute, Durham, North Carolina, USA.
Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, USA.
BMJ Support Palliat Care. 2018 Sep;8(3):274-277. doi: 10.1136/bmjspcare-2018-001509. Epub 2018 Apr 11.
Patients receiving induction chemotherapy for acute myeloid leukaemia (AML) anecdotally describe poor sleep, but sleep disturbances have not been well-characterised in this population. We aimed to test the feasibility of measuring sleep quality in AML inpatients using a wearable actigraphy device.
Using the Actigraph GT3X 'watch', we assessed the total sleep time, sleep onset latency, wake after sleep onset, number of awakenings after sleep onset and sleep efficiency for inpatients with AML receiving induction chemotherapy. We assessed patient self-reported sleep quality using the Pittsburgh Sleep Quality Index (PSQI).
Of the 12 patients enrolled, 11 completed all actigraphy and PSQI assessments, demonstrating feasibility. Patients wore the Actigraph device for a mean (SD) of 15.92 (8.3) days, and actigraphy measures suggested poor sleep. Patients had a median average awakening length of 6.92 min, a median number of awakenings after sleep onset of 4 and a median sleep onset latency of 10.8 min. Actual median sleep efficiency (0.91) was high, suggesting that patients' poor sleep was not due to insomnia but perhaps due to interruptions, such as administration of medications, lab draws and vital sign measurements.
Collection of sleep quality data among inpatients with AML via a wearable actigraphy device is feasible. AML inpatients appear to have poor sleep quality and quantity, suggesting that sleep issues represent an area of unmet supportive care needs in AML. Further research in this areas is needed to inform the development of interventions to improve sleep duration and quality in hospitalised patients with AML.
接受急性髓系白血病（AML）诱导化疗的患者称睡眠质量差，但该人群的睡眠障碍尚未得到充分描述。我们旨在测试使用可穿戴式活动记录仪测量AML住院患者睡眠质量的可行性。
我们使用活动记录仪Actigraph GT3X“手表”，评估接受诱导化疗的AML住院患者的总睡眠时间、入睡潜伏期、睡眠中觉醒时间、睡眠中觉醒次数和睡眠效率。我们使用匹兹堡睡眠质量指数（PSQI）评估患者自我报告的睡眠质量。
在纳入的12例患者中，11例完成了所有活动记录仪和PSQI评估，证明了可行性。患者佩戴Actigraph设备的平均（标准差）时间为15.92（8.3）天，活动记录仪测量结果显示睡眠质量差。患者的平均觉醒时长中位数为6.92分钟，睡眠中觉醒次数中位数为4次，入睡潜伏期中位数为10.8分钟。实际睡眠效率中位数（0.91）较高，表明患者睡眠质量差并非由于失眠，而是可能由于诸如给药、抽血和生命体征测量等干扰因素。
通过可穿戴式活动记录仪收集AML住院患者的睡眠质量数据是可行的。AML住院患者似乎睡眠质量和数量都较差，这表明睡眠问题是AML支持性护理需求中未得到满足的一个领域。需要在该领域进行进一步研究，为改善AML住院患者睡眠时间和质量的干预措施的制定提供依据。
